Cargando…
The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells
An oral antiviral against SARS-CoV-2 that also attenuates inflammatory instigators of severe COVID-19 is not available to date. Herein, we show that the apoA-I mimetic peptide 4 F inhibits Spike mediated viral entry and has antiviral activity against SARS-CoV-2 in human lung epithelial Calu3 and Ver...
Autores principales: | Theodoros, Kelesidis, Sharma, Madhav, Anton, Petcherski, Hugo, Cristelle, Ellen, O’Connor, Hultgren, Nan W, Ritou, Eleni, Williams, David S, Orian S, Shirihai, Srinivasa T, Reddy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437485/ https://www.ncbi.nlm.nih.gov/pubmed/34494942 http://dx.doi.org/10.1080/21505594.2021.1964329 |
Ejemplares similares
-
ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
por: Daskou, Maria, et al.
Publicado: (2022) -
ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV
por: Daskou, M., et al.
Publicado: (2021) -
ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016) -
HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015) -
An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration
por: Chen, Xun, et al.
Publicado: (2009)